黄伟莉

溶瘤病毒（Oncolytic virus，OV）作为新型免疫疗法，可直接裂解肿瘤细胞，通过激活肿瘤微环境中的炎症反应间接增强抗肿瘤免疫力。然而OV对肿瘤的杀伤力以及宿主抗病毒的免疫反应有限，若能解决这些问题，可能为临床提供强有力的平台。目前，多种上市溶瘤病毒产品表明，单纯疱疹病毒（herpes simplex virus，HSV）作为OV载体具有一定的有效性和安全性。在此，我们总结了以HSV为载体的溶瘤病毒研制，病毒递送新方式以及提高免疫反应的联合治疗方案，希望有助于进一步推广OV在癌症治疗中的应用。

溶瘤病毒；单纯疱疹病毒；屏蔽策略；联合治疗

[1] MARTIN N T, BELL J C. Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones [J]. Mol Ther, 2018, 26(6): 1414-22. [2] MONDAL M, GUO J, HE P, et al. Recent advances of oncolytic virus in cancer therapy [J]. Hum Vaccin Immunother, 2020, 16(10): 2389-402. [3] SHALHOUT S Z, MILLER D M, EMERICK K S, et al. Therapy with oncolytic viruses: progress and challenges [J]. Nat Rev Clin Oncol, 2023, 20(3): 160-77. [4] DUAN Q, ZHANG H, ZHENG J, et al. Turning Cold into Hot: Firing up the Tumor Microenvironment [J]. Trends Cancer, 2020, 6(7): 605-18. [5] MäRKL F, HUYNH D, ENDRES S, et al. Utilizing chemokines in cancer immunotherapy [J]. Trends Cancer, 2022, 8(8): 670-82. [6] NI L, LI Y, WU K, et al. Antitumor efficacy of CRISPR/Cas9-engineered ICP6 mutant herpes simplex viruses in a mouse xenograft model for lung adenocarcinoma [J]. J Med Virol, 2022, 94(12): 6000-15. [7] ANDTBACKA R H, KAUFMAN H L, COLLICHIO F, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma [J]. J Clin Oncol, 2015, 33(25): 2780-8. [8] ANDTBACKA R H I, COLLICHIO F, HARRINGTON K J, et al. Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III-IV melanoma [J]. J Immunother Cancer, 2019, 7(1): 145. [9] MACEDO N, MILLER D M, HAQ R, et al. Clinical landscape of oncolytic virus research in 2020 [J]. J Immunother Cancer, 2020, 8(2). [10] EISSA I R, BUSTOS-VILLALOBOS I, ICHINOSE T, et al. The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers [J]. Cancers (Basel), 2018, 10(10).

点击下载PDF